Ophtascan

Ophtascan The world’s first clinically tested and validated on-demand cancer and diabetes screening system powe In the fight against cancer, early detection is pivotal.

Ophtascan by OncoTech – the vanguard of cancer and diabetes early detection. Our AI-powered system is the first of its kind, clinically tested and validated to provide on-demand screening with precision and ease. It's not just about creating advanced technology; it's about delivering hope and saving lives. Ophtascan represents a leap forward in medical innovation, making comprehensive screening mo

re accessible and efficient than ever before. Our commitment goes beyond innovation. In a world where cancer remains a leading cause of death, we strive to bridge the gap in healthcare disparities. Ophtascan is designed to be a cost-effective solution, bringing life-saving diagnostics to communities worldwide, no matter their socioeconomic status. With Ophtascan, we're not just imagining a world where cancer is conquered—we're actively expanding across the world. Stay updated on our progress, learn about our technology, and join us on this transformative journey towards a cancer free future. For more information, visit Ophtascan.ai.

Happy New Year! 🎉Stepping into 2026 with renewed focus on innovation, precision, and better health outcomes through AI-d...
01/01/2026

Happy New Year! 🎉

Stepping into 2026 with renewed focus on innovation, precision, and better health outcomes through AI-driven screening.

Wishing you and yours a happy holiday season! 🎄This year, we at Oncotech have made great progress in several markets in...
25/12/2025

Wishing you and yours a happy holiday season! 🎄

This year, we at Oncotech have made great progress in several markets including regulatory approvals, ministry of health approvals as well as launch of new clinical validations in new markets.

As we look to the new year, we are excited for commercially implementing in several countries.

All of this is only possible thanks to the support of people like you. We at Oncotech are grateful to you for joining our mission to conquer cancer.

Wishing you and yours a very happy holidays and a new year of great success and even greater health!

From,
All of us at Oncotech

🧪 We’re hiring in Sri Lanka! Join Oncotech as a Clinical Research Assistant (Contract Basis) and be part of our mission ...
06/11/2025

🧪 We’re hiring in Sri Lanka!

Join Oncotech as a Clinical Research Assistant (Contract Basis) and be part of our mission to advance AI-powered early cancer detection.

📍 Openings in Jaffna, Vavuniya, Batticaloa, Kurunegala, Maharagama, and Galle

🎓 Ideal for new graduates in Medicine, Nursing, Biomedical, or Allied Health
📅 6-month full-time, on-site contract

Gain hands-on experience in clinical data collection and research while contributing to a global MedTech breakthrough. 🌍

👉 Apply now: oncotech.global/careers

🚀 We’re hiring in Sri Lanka! Join Oncotech as a Project Coordinator – Technical Verification & Clinical Validation (Opht...
06/11/2025

🚀 We’re hiring in Sri Lanka!

Join Oncotech as a Project Coordinator – Technical Verification & Clinical Validation (Ophtascan™).

Be part of a global MedTech team making AI-powered early cancer detection accessible worldwide. 🌍

👉 Apply now: oncotech.global/careers

At the Cancer Genomics Conference in Namibia, our Co-Founder Bren Sambunathan joined the Expert Panel Discussion on “Rol...
28/09/2025

At the Cancer Genomics Conference in Namibia, our Co-Founder Bren Sambunathan joined the Expert Panel Discussion on “Role of AI Technology in Cancer Screening and Treatment.”

He shared how AI can support earlier detection, precision diagnostics, and more equitable access to care — and how collaboration between governments, academia, and innovators is essential to achieve large-scale impact.

🌍 Ophtascan at the Cancer Genomics Conference 2025Our Co-Founder Bren Sambunathan delivered a presentation at the Cancer...
28/09/2025

🌍 Ophtascan at the Cancer Genomics Conference 2025

Our Co-Founder Bren Sambunathan delivered a presentation at the Cancer Genomics Conference in Namibia on how AI is transforming inclusive cancer research across the African region.

With AI-driven platforms, we’re helping researchers and health systems accelerate functional genomics, improve evidence-based decisions, and drive better outcomes for patients across Africa. 💙

26/09/2025

Ophtascan at the NUST Cancer Genomics Conference Dinner 🌟

We were delighted to join fellow innovators, researchers, and healthcare leaders at the NUST Cancer Genomics Conference dinner. It was a wonderful opportunity to build connections, exchange ideas, and explore collaborations that can advance early detection and diagnostic solutions in oncology.

Together with our peers, we’re continuing to push the boundaries of technology-enabled cancer research and care.

Ophtascan at the 2025 NUST Cancer Genomics Conference — connecting with innovators in precision oncology.We’re honored t...
26/09/2025

Ophtascan at the 2025 NUST Cancer Genomics Conference — connecting with innovators in precision oncology.

We’re honored to present our advanced diagnostic and early-detection solutions that support researchers, clinicians, and institutions in pushing the boundaries of cancer science. Together, we strive to make cancer diagnostics more accessible, actionable, and impactful — without offering direct cancer therapies.

🌍 Oncotech at the Cancer Genomics Conference 2025We’re proud to announce that our Co-Founder, Mr. Bren Sambunathan, will...
12/09/2025

🌍 Oncotech at the Cancer Genomics Conference 2025

We’re proud to announce that our Co-Founder, Mr. Bren Sambunathan, will be sharing insights at the Cancer Genomics Conference taking place from 24–26 September 2025 in Namibia. He will discuss how AI is transforming inclusive cancer research across the African region.

🧬 Why this matters:
Cancer genomics is a critical topic at this point in time that will have a great impact on Namibia and the African continent, where we are now seeing a sudden rise in cancer cases. Understanding the recent advancements in functional genomics could lead to more effective cancer therapeutic strategies and better outcomes for patients across the region.

Let’s work together to advance inclusive, AI-driven cancer research in Africa. 💙

Address

1 Charterhouse Mews
London
EC1M6BB

Website

Alerts

Be the first to know and let us send you an email when Ophtascan posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Shortcuts

Share

Category